Autoimmunity in chronic lymphocytic leukemia
- 68 Downloads
Chronic lymphocytic leukemia (CLL) is associated with the immune-mediated disorders autoimmune hemolytic anemia and immune thrombocytopenia. Initial treatment with corticosteroids is often successful in controlling these manifestations, but splenectomy should be considered if a rapid and complete response is not obtained. For those with persistent anemia or thrombocytopenia after splenectomy, treatment directed against the underlying CLL may be considered, although the use of purine analogues has also precipitated autoimmune hemolytic anemia. Pure red cell aplasia has been reported in CLL, and usually responds to immunosuppressive therapy.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 6.Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000, 95:2786–2792. This study reviews AIHA in a series of 1203 patients with CLL, and details the risk factors and treatment. This series suggests that steroids may be more useful in CLL-associated AIHA than in AIHA without an associated lymphoproliferative disorder.PubMedGoogle Scholar
- 7.Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998, 25:80–97. This recent review article details autoimmune disease associated with CLL as well as other hematopoietic malignancies. A comprehensive list of interventions and their results is provided, with 151 references.PubMedGoogle Scholar
- 8.Zipps T, Carson DA: Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993, 81:2475–2487.Google Scholar
- 9.Rai KR, Peterson BL, Frederick R, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750–1757. This randomized, prospective trial of 509 patients represents the most recent and best data about treatment of CLL, suggesting better response rates and longer remissions with fludarabine, but no change in overall survival.PubMedCrossRefGoogle Scholar